成果報告書詳細
管理番号20130000000252
タイトル*平成24年度中間年報 「がん超早期診断・治療機器の総合研究開発 超早期高精度診断システムの研究開発:画像診断システムの研究開発 がんの性状をとらえる分子プローブ等の研究開発(がんの特性識別型分子プローブ) 」
公開日2014/6/14
報告書年度2012 - 2012
委託先名国立大学法人京都大学
プロジェクト番号P10003
部署名バイオテクノロジー・医療技術部
和文要約
英文要約(1) Development of molecular imaging probes targeting pancreatic cancer.
Due to the asymptomatic onset of pancreatic cancer, the majority of patients are in an advanced or metastatic condition at the time of diagnosis, resulting in poor prognosis. Earlier diagnosis and better treatments are needed urgently to improve the survival rate of patients with pancreatic cancer. We therefore developed molecular probes for the early detection of pancreatic cancer. This involved the design and synthesis of molecular probes targeting 1) the integrin αVβ6 which is involved in tumor progression of pancreatic ductal carcinoma, and 2) the GLP-1 receptor which is expressed in pancreatic endocrine tumors.
・ For the integrin probe, radioiodinated peptide probes were synthesized successfully. An in vivo imaging study on mice with subcutaneously-implanted cancers provided SPECT images of tumors expressing the integrin αVβ6.
・ For the GLP-1 receptor probe, an extended single-dose toxicity study revealed no abnormal findings for [123I]IB12-Ex(9-39). 68Ga-Df9-Ex(9-39) was synthesized successfully. An in vivo imaging study using mice with subcutaneously-implanted cancer showed a clear PET image of tumors expressing GLP-1. PET images were also obtained using a principle verification machine of flexible PET developed by Shimadzu Co.
(2) Development of molecular imaging probes targeting lung cancer.
A molecular-targeted approach has already been established for treatment of lung cancer. There is an increased expectation for personalized medicine for lung cancer based on prediction of its therapeutic effects. The aim of our research was to develop molecular imaging probes targeting EGFR or PI3K.
(3) Development of molecular imaging probes targeting breast cancer.
A molecular-targeted approach has been established previously for treatment of breast cancer. There is an increased expectation for personalized medicine for breast cancer based on prediction of its therapeutic effects. We therefore designed and synthesized molecular probes targeting human epidermal growth factor receptor (HER2) or membrane type-1 matrix metalloproteinase (MT-1 MMP).
(4) Development of molecular imaging probes targeting prostate cancer.
Treatment strategies for prostate cancer are determined based on risk assessment. We developed molecular probes for prostate cancer that involved designing a low molecular weight probe that targeted prostate-specific membrane antigen (PSMA). This probe was expected to have better biokinetics than existing probes.
(5) Development of molecular imaging probes targeting the hypoxic microenvironment associated with cancer.
A hypoxic microenvironment develops in various types of solid tumors as abnormal proliferation outstrips the blood supply. As this hypoxic region is involved in tumor malignancy, we developed molecular probes for hypoxic microenvironments.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る